← 產業報告目錄
Radioligand Therapy Market Size, Share & Trends Analysis Report By Target(Prostate-Specific Membrane Antigen, Cancerous bone lesions, Somatostatin receptor type 2 (SSTR2)), By Indications, By Products, By Emission By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-03頁數 180報告編號 INSIGHTACE-a4d6e88372
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Radioligand Therapy Market stood at USD 2.31 Billion in 2024, and is set to reach USD 8.33 Billion by 2034, recording a CAGR of 12.1% from 2025 through 2034.
At its core, Radioligand Therapy pertains to a cancer treatment strategy that uses targeted medicines. Stakeholders across the healthcare landscape are escalatingly turning to these solutions to meet contemporary demands.
Market momentum is bolstered by escalating appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radioligand Therapy Market Snapshot
Chapter 4. Global Radioligand Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Target, Estimates & Trend Analysis
5.1. By Target, & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Target:
5.2.1. Prostate-Specific Membrane Antigen
5.2.2. Cancerous bone lesions
5.2.3. Somatostatin receptor type 2 (SSTR2)
Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis
6.1. By Indications & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Indications:
6.2.1. Prostate Cancer
6.2.2. Neuroendocrine Tumor (NETs)
6.2.3. Others Indications
Chapter 7. Market Segmentation 3: By Products Estimates & Trend Analysis
7.1. By Products & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Products:
7.2.1. Approved Products
7.2.1.1. Lutathera
7.2.1.2. Zytiga
7.2.1.3. Xtandi
7.2.1.4. Xofigo
7.2.2. Potential Pipeline
Chapter 8. Market Segmentation 4: By Products Estimates & Trend Analysis
8.1. By Products & Market Share, 2021 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Products:
8.2.1. Alpha
8.2.2. Beta
8.2.3. Potential Pipeline
Chapter 9. Radioligand Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Target, 2021-2034
9.1.2. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
9.1.3. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
9.1.4. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts By Emission, 2021-2034
9.1.5. North America Radioligand Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Radioligand Therapy Market revenue (US$ Million) By Target, 2021-2034
9.2.2. Europe Radioligand Therapy Market revenue (US$ Million) By Indications, 2021-2034
9.2.3. Europe Radioligand Therapy Market revenue (US$ Million) By Products, 2021-2034
9.2.4. Europe Radioligand Therapy Market revenue (US$ Million) By Emission, 2021-2034
9.2.5. Europe Radioligand Therapy Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
9.3.1. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Target, 2021-2034
9.3.2. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Indications, 2021-2034
9.3.3. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Products, 2021-2034
9.3.4. Asia Pacific Radioligand Therapy Market revenue (US$ Million) By Emission, 2021-2034
9.3.5. Asia Pacific Radioligand Therapy Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
9.4.1. Latin America Radioligand Therapy Market revenue (US$ Million) By Target, (US$ Million) 2021-2034
9.4.2. Latin America Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
9.4.3. Latin America Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
9.4.4. Latin America Radioligand Therapy Market revenue (US$ Million) By Emission, (US$ Million) 2021-2034
9.4.5. Latin America Radioligand Therapy Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
9.5.1. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Target, (US$ Million) 2021-2034
9.5.2. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
9.5.3. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Products, (US$ Million) 2021-20341
9.5.4. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) By Emission, (US$ Million) 2021-2034
9.5.5. Middle East & Africa Radioligand Therapy Market revenue (US$ Million) by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Novartis AG
10.2.2. Bayer AG
10.2.3. Telix Pharmaceuticals
10.2.4. ITM Isotope Technologies
10.2.5. Eli Lilly (via POINT Biopharma)
10.2.6. AstraZeneca (via Fusion Pharmaceuticals)
10.2.7. Radiopharm Theranostics
10.2.8. Nordic Nanovector
10.2.9. Y-mAbs Therapeutics
10.2.10. Ratio Therapeutics
10.2.11. Radionetics Oncology
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們